Liver Cancer Treatment Market: By Diseases Type (Primary, Secondary, and Benign Liver Growths), By Therapeutics (Sorafenib Tosylate, Regorafenib, Doxorubicin, 5-Fluorouracil, Cisplatin, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) and Geography  

Liver Cancer Treatment Market size was estimated at USD 2.2 billion in 2022 and is poised to grow at a CAGR of 19.0% from 2023-2029. Liver cancer is also known as hepatic cancer. Upon liver cancer diagnosis different treatment methods are adapted like tumor embolization, surgery, targeted therapy, immunotherapy, chemotherapy for treating the disease, extending the life span, or relieving symptoms of the patients. The early stage of liver cancer shows no symptoms and usually appears in the late stage which leads to an increased patient volume available for liver cancer treatment. Exposure to environmental chemicals like vinyl chloride, and benzene, and lifestyle changes expose people to the risk of liver cancer. In addition to curative treatments, physicians are looking for new treatment options like neoadjuvant and adjuvant therapies to boost the chances of survival rate. Liver Cancer Treatment Market players are focused on developing new drugs that work by targeting specific parts of cancer cells or their surrounding environment. Nexavar and miripla act by hindering new blood vessels and thereby tumor growth is being studied for use in the early stages of cancer.

The pipeline includes drugs like Thermodox, ImClone Afinitor by Celsion, Eli Lilly, and Novartis respectively which show potential to capture the targeted liver cancer drug market. Regorafenib (Stivarga) is a targeted drug, used to treat liver cancers that are no longer responding to sorafenib. Cabozantinib is another targeted drug that has been shown to reduce tumor growth and stop new blood vessel growth in some studies. Chemotherapy drugs, such as oxaliplatin, capecitabine, gemcitabine, and docetaxel, are being tested against liver cancer in clinical trials. Oxaliplatin has shown promising results in early studies when given in combination with doxorubicin and also when given with gemcitabine and the targeted therapy drug cetuximab (Erbitux). In 2017, The U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab), a monoclonal antibody, which is a type of immunotherapy, to treat liver cancer.  Important drivers for the market are the increasing aging population, drug inventions with respect to cancer, increasing government initiatives, rising prevalence of cancer, and increasing healthcare expenditure. However, factors such as stringent regulatory processes, high capital investments, low success rates in clinic trials for drugs, and low reach in remote areas are hindering the growth of the market.